Furthermore, compared with a recent meta-analysis ofTang et al. (2018),which determined whether ABCG2 gene polymorphisms are associatedwith the risk of gefitinib-induced toxicity in NSCLC patients, our study addedmeta-analysis of survival outcomes. Here, ABCG2 is linked to non-small cell lung carcinoma.